Company
Vivacelle Bio
Vivacelle Bio is a late-stage biopharma company developing life-saving treatments for shock and trauma.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- Kansas City, MO, United States
Claim, correct or request removal
Record updated 28 September 2026
About
The company’s lead, Phase 3 product, VBI-S, is built on its pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to elevate blood pressure in hypovolemic septic shock, a leading cause of death that impacts millions around the world.
Funding snapshot
- Total raised
- $4.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $2.9M2016-08-05
Funding rounds
- Round, 2016
- $2.9M2016-08-05, SEC form D sold, 59 investors
- Round, 2014
- $1.3M2014-01-31, SEC form D sold, 58 investors
Products
- Other
- VBI-S
Loading relationship preview